GC - GC vitamin D binding protein Gene
生物種: Bos taurus
遺伝子タイプ: protein coding
遺伝子ID: 530076
GC Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001035380.2 | NP_001030457.1 | vitamin D-binding protein precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
vitamin D-binding protein |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(5)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0561 | Spironolactone | 99.81% | Yes | |
| HY-13693 | Mometasone furoate | Agonist | 99.90% | Yes |
| HY-108741 | Plecanatide | Agonist | 99.93% | Unkown |
| HY-17569 | Difluprednate | Inhibitor | 99.63% | Yes |
| HY-108741A | Plecanatide acetate | Agonist | 99.70% | Unkown |
Clinical Phase
Bioactive Molecules
(14)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-141642 | Triheptadecanoin | 98.0% | Phase 4 | |
| HY-109110 | Avasopasem manganese | 96.07% | Phase 3 | |
| HY-P99013 | Codrituzumab | Inhibitor | 99.07% | Phase 2 |
| HY-14823 | Sobetirome | Agonist | 99.91% | Phase 2 |
| HY-13336 | Imisopasem manganese | 96.33% | Phase 2 | |
| HY-P0118 | Disitertide | 98.03% | Phase 2 | |
| HY-14181A | Cinaciguat hydrochloride | Activator | 98.90% | Phase 2 |
| HY-132829 | Rucosopasem manganese | / | Phase 2 | |
| HY-10498A | Lexibulin dihydrochloride | / | Phase 2 | |
| HY-145381 | 11β-HSD1-IN-6 | Inhibitor | / | Phase 2 |
| HY-P3499 | Dolcanatide | Agonist | 99.20% | Phase 1 |
| HY-12946A | BI 653048 phosphate | Inhibitor | / | Phase 1 |
| HY-187243A | DMG-PEG2000-LyP-1 | / | Phase 1 | |
| HY-187318C | DOPE-PEG5000-LyP-1 | / | Phase 1 |
阻害性抗体
(3)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-P99693 | Lenvervimab | Inhibitor | ≥99% | Phase 3 |
| HY-P99020 | Fresolimumab | Inhibitor | 99.51% | Phase 2 |
| HY-P991571 | GC1118 | Inhibitor | 99.22% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(95)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-108314A | GC7 Sulfate | Inhibitor | 98.0% | Unkown |
| HY-D1020 | 7-Aminoactinomycin D | Inhibitor | ≥99.0% | Unkown |
| HY-136684 | BrBzGCp2 | Inhibitor | 99.00% | Unkown |
| HY-111798 | Heme Oxygenase-1-IN-1 | Inhibitor | 99.13% | Unkown |
| HY-141513 | NH-3 | Antagonist | 99.41% | Unkown |
| HY-100721 | GC376 sodium | Inhibitor | 99.53% | Unkown |
| HY-W127512 | 5β-Cholanic acid | 99.87% | Unkown | |
| HY-111798A | Heme Oxygenase-1-IN-1 hydrochloride | Inhibitor | 99.03% | Unkown |
| HY-13963 | ZCL278 | Inhibitor | 98.49% | Unkown |
| HY-111208 | CCT129957 | Inhibitor | 99.16% | Unkown |
| HY-P0118B | Disitertide diammonium | 99.00% | Unkown | |
| HY-W040129 | Chromomycin A3 | 99.66% | Unkown | |
| HY-108628 | SU16f | Inhibitor | 99.36% | Unkown |
| HY-D1191 | SYBR green I chloride | 98.09% | Unkown | |
| HY-10498 | Lexibulin | 99.10% | Unkown | |
| HY-132184 | 5,6-Epoxyeicosatrienoic acid | Inhibitor | 99.9% | Unkown |
| HY-W089645 | 2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide | 98.79% | Unkown | |
| HY-W004290 | Methyl heptadecanoate | 99.69% | Unkown | |
| HY-I0450 | Anticancer agent 265 | 99.64% | Unkown | |
| HY-W004290S | Methyl heptadecanoate-d33 | 99.52% | Unkown | |
| HY-152038 | SPEN-IN-1 | Inhibitor | 97.25% | Unkown |
| HY-130189 | S-Phenylmercapturic acid | 99.38% | Unkown | |
| HY-113422 | Tetrahydrocorticosterone | 99.90% | Unkown | |
| HY-76476 | (S)-Tetrahydrofuran-3-ol | 99.94% | Unkown | |
| HY-149453 | MCUF-651 | Modulator | 99.85% | Unkown |
| HY-131389 | Cholesteryl heptadecanoate | 98.0% | Unkown | |
| HY-DY1099 | 7-Aminoactinomycin D (solution) | Inhibitor | / | Unkown |
| HY-12946 | BI 653048 | Inhibitor | 99.84% | Unkown |
| HY-114043 | NCGC00092410 | Inhibitor | 98.10% | Unkown |
| HY-160178 | Glucocorticoid receptor agonist-3 Ala-Ala-Mal | 99.70% | Unkown | |
| HY-155789 | C17 Globotriaosylceramide (d18:1/17:0) | ≥99.0% | Unkown | |
| HY-108314 | GC-7 | Inhibitor | / | Unkown |
| HY-151482 | SARS-CoV-2 Mpro-IN-2 | Inhibitor | 98.96% | Unkown |
| HY-107547 | BPIPP | Inhibitor | 98.3% | Unkown |
| HY-113422S | Tetrahydrocorticosterone-d5 | 97.45% | Unkown | |
| HY-114577 | Palifosfamide tromethamine | Chemical | 98.74% | Unkown |
| HY-B0561S4 | Spironolactone-d6-1 | 99.26% | Unkown | |
| HY-N6651 | Isocryptotanshinone | ≥98.0% | Unkown | |
| HY-P0118A | Disitertide TFA | / | Unkown | |
| HY-123023 | 12(S)-HETE-d8 | Inducer | 98.00% | Unkown |
| HY-N10220 | Paraherquamide E | 95.0% | Unkown | |
| HY-W712028 | α-Thujene | 95.0% | Unkown | |
| HY-101282 | Glutaminyl Cyclase Inhibitor 3 | Inhibitor | / | Unkown |
| HY-108353S | Isoprenaline-d7 acetate | / | Unkown | |
| HY-111442 | GC 14 | Antagonist | / | Unkown |
| HY-113422S1 | Tetrahydrocorticosterone-d3 | / | Unkown | |
| HY-113422S2 | Tetrahydrocorticosterone-d3-1 | / | Unkown | |
| HY-118274 | ADDA | / | Unkown | |
| HY-130229 | (±)5,6-DHET lactone | / | Unkown | |
| HY-13963S | ZCL278-13C | / | Unkown | |
| HY-141717 | α-cis-Bergamotene | / | Unkown | |
| HY-146398 | AMPK activator 6 | Activator | / | Unkown |
| HY-14823G | Sobetirome (GMP) | Agonist | / | Unkown |
| HY-148392 | Neu5Gcα(2-6) N-Glycan-Asn | / | Unkown | |
| HY-149774 | GC-78-HCl | / | Unkown | |
| HY-156020 | Glucocerebrosidase-IN-2 | Inhibitor | / | Unkown |
| HY-157001 | 7-Deaza-dGTP tetralithium | / | Unkown | |
| HY-160180 | Glucocorticoid receptor agonist-4 Ala-Ala-Mal | / | Unkown | |
| HY-162293 | CDK8-IN-14 | Inhibitor | / | Unkown |
| HY-166965 | Neu5Gc(α2,6)N-Acetylgalactosamine | / | Unkown | |
| HY-17569S2 | Difluprednate-d3-1 | Inhibitor | / | Unkown |
| HY-178738 | GC-072 | Inhibitor | / | Unkown |
| HY-179535 | Axl-IN-21 | Inhibitor | / | Unkown |
| HY-186299 | β-Sitosteryl linoleate | Inhibitor | / | Unkown |
| HY-187243 | DMG-PEG1000-LyP-1 | / | Unkown | |
| HY-187243B | DMG-PEG3400-LyP-1 | / | Unkown | |
| HY-187243C | DMG-PEG5000-LyP-1 | / | Unkown | |
| HY-187318 | DOPE-PEG1000-LyP-1 | / | Unkown | |
| HY-187318A | DOPE-PEG2000-LyP-1 | / | Unkown | |
| HY-187318B | DOPE-PEG3400-LyP-1 | / | Unkown | |
| HY-187321A | DPPE-PEG2000-LyP-1 | / | Unkown | |
| HY-187332A | DSG-PEG2000-LyP-1 | / | Unkown | |
| HY-N15629 | Melicopicine | / | Unkown | |
| HY-N15820 | C18:0 GM1(Neu5Gc) Ceramide (d18:1/18:0) | / | Unkown | |
| HY-N15822 | C18:0 GM3(Neu5Gc) Ceramide (d18:1/18:0) | / | Unkown | |
| HY-N15823 | C18:0 GM2(Neu5Gc) Ceramide (d18:1/18:0) | / | Unkown | |
| HY-N18337 | Salidroside 3-O-glucopyranoside | / | Unkown | |
| HY-P10786 | LinTT1 peptide | Inhibitor | / | Unkown |
| HY-P1911 | CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156) | / | Unkown | |
| HY-RS05316 | GC Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W127357 | Tripelargonin | / | Unkown | |
| HY-W127496 | Methyl 13-methyltetradecanoate | / | Unkown | |
| HY-W130478S | 1-Phenylhexane-d5 | / | Unkown | |
| HY-120410 | DL-4662 | / | Unkown | |
| HY-154171 | Deoxyribosyl dihydropyrimido[4,5-c][1,2]oxazin-7-one | 99.87% | Unkown | |
| HY-165420 | GC-IN-2 | Inhibitor | / | Unkown |
| HY-183956 | GC813 | Inhibitor | / | Unkown |
| HY-185963 | ABE8e mRNA (N1-methyl-pseudouridine) | / | Unkown | |
| HY-187697 | DB1255 | Inhibitor | / | Unkown |
| HY-N10626 | Neu5Gcα(2-6) N-Glycan | / | Unkown | |
| HY-RS16765 | Gc Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20039 | Il2rg Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20738 | Gba1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23205 | Gc Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W099771 | 4-Propylanisole | 99.05% | Unkown |
阻害性抗体
(3)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P991302 | KL-A289 | Inhibitor | / | Unkown |
| HY-P990844 | Anti-GC1q R/C1QBP Antibody (60.11) | Inhibitor | / | Unkown |
| HY-P991482 | ADI-42898 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service